Preferencje help
Widoczny [Schowaj] Abstrakt
Liczba wyników
2015 | 28 | 4 | 231-235
Tytuł artykułu

In vitro study: binding of99mTc-DPD to synthetic amyloid fibrils

Treść / Zawartość
Warianty tytułu
Języki publikacji
This paper is an report of the investigation of the in vitro binding of 99mTc-DPD for synthetic amyloid fibrils used for the diagnosis of cardiac amyloidosis (CA), as compared with the use of 99mTc-HMDP and 99mTc-PPI. It also includes an inquiry into the role played by Ca2+ ions and serum proteins on binding to amyloid like materials, as well as the saturability and specificity of DPD for fibrils versus amorphous precipitates (AP). In the work, synthetic insulin fibrils (SIF) and AP were characterized by Congo red staining and TEM imaging. An equal amount of three radiopharmaceuticals were then added to fibrils in Ca2+ (0-4.2 mmol/L) or human serum (HS) adjoined samples and radiopharmaceutical uptake was assessed. To test the saturability of amyloid binding sites, a displacement assays with cold DPD was performed, while adding 50-1500 nmol of 99mTc-DPD to SIF or AP, saturation binding tests were subsequently carried out for evaluating its specificity for amyloid. Herein, synthetic fibrils and AP showed conformational differences at TEM and polarized microscopy analysis. In our study, 99mTc-DPD fibrils uptake was seen to be the highest and increased with calcium ions concentration. What is more, serum proteins reduced the bound fraction to the amyloid deposits of about 15%, and the Kd values of 90 nM and 114 nM relative to SIF and AP, respectively, did not significantly differ. We saw that 99mTc-DPD is the best seeker for amyloid fibrils in cardiac amyloidosis, and that Ca2+ concentration positively influenced DPD fibrils binding. Furthermore, the radioactivity bound to the serum protein clear up the idea of nuclide exchanging dynamic balance between amyloid and circulating proteins. Moreover, non-labeled DPD did not exert a competition for 99mTc-DPD binding sites, and, finally, DPD cannot be defined a radiopharmaceutical specific for amyloid deposits.

Opis fizyczny
  • Department of Oncohaematology, Nuclear Medicine Unit, IRCCS San Matteo Hospital Foundation, V.le Golgi 19, 27100, Pavia, Italy
  • Department of Oncohaematology, Nuclear Medicine Unit, IRCCS San Matteo Hospital Foundation, V.le Golgi 19, 27100, Pavia, Italy
  • Department of Oncohaematology, Nuclear Medicine Unit, IRCCS San Matteo Hospital Foundation, V.le Golgi 19, 27100, Pavia, Italy,
  • Center for Inherited Cardiovascular Diseases, IRCCS San Matteo Hospital Foundation, V.le Golgi 19, 27100, Pavia, Italy
  • Department of Oncohaematology, Nuclear Medicine Unit, IRCCS San Matteo Hospital Foundation, V.le Golgi 19, 27100, Pavia, Italy
  • 1. Ak I. et al.: Myocardial Tc-99m MDP uptake on a bone scan in senile systemic amyloidosis with cardiac involvement. Clin. Nucl. Med., 25, 10, 2000.[Crossref]
  • 2. Aprile C. et al.: Accumulation of 99mTc-Sn Pyrophosphate in pleural effusion. Eur. J. Nucl. Med., 3, 4, 1978.
  • 3. Bokhari S. et al.: 99mTc-pyrophosphate scintigraphy for differentiating light-chain cardiac amyloidosis from the transthyretin-related familial and senile cardiac amyloidoses. Circ. Cardiovasc. Imaging, 6, 2, 2013.[Crossref]
  • 4. Casset-Senon D. et al.: Localization of myocardial amyloid deposits in cardiac amyloidosis by Tc-99m pyrophosphate myocardial SPECT: implication for medical treatment. Clin. Nucl. Med., 30, 7, 2005.
  • 5. Djokić D.D., Janković D.L., Nikolić N.S.: Labeling, characterization, and in vivo localization of a new 90Y-based phosphonate chelate 2,3-dicarboxypropane-1,1-diphosphonic acid for the treatment of bone metastases: Comparison with 99mTc-DPD complex. Bioorg. Med. Chem., 16, 8, 2008.
  • 6. Dubrey S.W. et al.: Familial and primary (AL) cardiac amyloidosis: echocardiographically similar diseases with distinctly different clinical outcomes. Heart, 78, 1, 1997.[Crossref]
  • 7. Falk R.: Cardiac technetium-99m pyrophosphate scintigraphy in familial amyloidosis. Am. J. Cardiol., 54, 8, 1984.[Crossref]
  • 8. Falk R. et al.: Sensitivity of technetium-99m-pyrophosphate scintigraphy in diagnosing cardiac amyloidosis. Am. J. Cardiol., 51, 5, 1983.[Crossref]
  • 9. Fogelman I. et al.: A comparison of skeletal uptakes of three diphosphonates by whole-body retention: concise communication. J. Nucl. Med., 22, 10, 1981.
  • 10. Fournier C. et al.: Usefulness of technetium-99m pyrophosphate myocardial scintigraphy in amyloid polyneuropathy and correlation with echocardiography. Am. J. Cardiol., 72, 11, 1993.[Crossref]
  • 11. Francis M.D. et al.: Comparative evaluation of three diphosphonates: in vitro adsorption (C-14 labeled) and in vivo osteogenic uptake (Tc-99m complexed). J. Nucl. Med., 21, 12, 1980.
  • 12. Gertz M. et al.: Utility of technetium Tc-99m pyrophosphate bone scanning in cardiac amyloidosis. Arch. Intern. Med., 147, 6, 1987.[Crossref]
  • 13. Glaudemans A.W. et al.: Nuclear imaging in cardiac amyloidosis. Eur. J. Nucl. Med. Mol. Imaging, 36, 4, 2009.
  • 14. Grudzielanek S. et al.: Cytotoxicity of insulin within its self-assembly and amyloidogenic pathways. J. Mol. Biol., 370, 2, 2007.[Crossref][WoS]
  • 15. Hongo M. et al.: Cardiac involvement in systemic amyloidosis: myocardial scintigraphic evaluation. J. Cardiogr., 15, 1, 1985.
  • 16. Iannuzzi C., Irace G., Sirangelo I.: The effect of glycosaminoglycans (GAGs) on amyloid aggregation and toxicity. Molecules, 20, 2, 2015.[Crossref][WoS]
  • 17. Jurisson S.S. et al.: Calcium affinity of coordinated diphosphonate ligands. Single-crystal structure of [(en)2Co(02P(OH)CH2P(OH)02)] ClO4.H2O. Implication for the chemistry of technetium-99mdiphosphonate skeletal imaging agents. Inorg. Chem., 22, 9, 1983.
  • 18. Kristen A.V. et al.: Non-invasive predictors of survival in cardiac amyloidosis. Eur. J. Heart Fail., 9, 6, 2007.[WoS][Crossref]
  • 19. Kroesbergen J. et al.: 99mTc bone scanning agents--VI. Gel chromatographic analysis of the plasma protein binding of 99mTc(Sn)pyrophosphate, 99mTc(Sn)MDP and 99mTc(Sn)HMDP. Int. J. Rad. Appl. Instrum. B, 15, 5, 1988.
  • 20. Kula R.W., Engel W.K., Line B.R.: Scanning for soft-tissue amyloid. Lancet, 1, 8002, 1977.
  • 21. Martin Jr J.L et al.: Technetium-diphosphonate skeletal imaging agents: EXAFS structural studies in aqueous solution. Inorg. Chem., 28, 15, 1989.[Crossref]
  • 22. Merlini G., Bellotti V.N.: Molecular mechanisms of amyloidosis. Engl. J. Med., 349, 6, 2003.[Crossref]
  • 23. Ng B. et al.: Senile systemic amyloidosis presenting with heart failure: a comparison with light chain associated amyloidosis. Arch. Intern. Med., 165, 12, 2005.[Crossref]
  • 24. Perugini E. et al.: Noninvasive etiologic diagnosis of cardiac amyloidosis using 99mTc-3,3-diphosphono-1,2-propanodicarboxylic acid scintigraphy. J. Am. Coll. Cardiol., 46, 6, 2005.
  • 25. Pinkerton T.C. et al.: Bioinorganic activity of technetium radiopharmaceuticals. J. Chem. Educ., 62, 11, 1985.
  • 26. Puille M. et al. 99mTc-DPD scintigraphy in transthyretin-related familial amyloidotic polyneuropathy. Eur. J. Nucl. Med. Mol. Imaging, 29, 3, 2002.
  • 27. Rapezzi C. et al.: Usefulness of 99mTc-DPD scintigraphy in cardiac amyloidosis. J. Am. Coll. Cardiol., 51, 15, 2008.[Crossref]
  • 28. Rapezzi C. et al.: Usefulness and limitations of 99mTc-3,3- diphosphono-1,2-propanodicarboxylic acid scintigraphy in the aetiological diagnosis of amyloidotic cardiomyopathy. Eur. J. Nucl. Med. Mol. Imaging, 38, 3, 2011.
  • 29. Rossi P. et al.: 99mTc DPD is the preferential bone tracer for diagnosis of cardiac transthyretin amyloidosis. Clin. Nucl. Med., 37, 8, 2012.[Crossref]
  • 30. Sipe J.D. et al.: Nomenclature 2014: Amyloid fibril proteins and clinical classification of the amyloidosis. Amyloid, 21, 4, 2014.[WoS][Crossref]
  • 31. Westermark P. Subcutaneous adipose tissue biopsy for amyloid protein studies. Methods Mol. Biol., 849, 2012.[WoS]
  • 32. Wilson G.M., Pinkerton T.C.: Determination of charge and size of technetium diphosphonate complexes by anion-exchange liquid chromatography. Anal. Chem., 57, 1, 1985.[Crossref]
  • 33. Yood R.A. et al.: Soft tissue uptake of bone seeking radionuclide in amyloidosis. J. Rheumatol., 8, 5, 1981.
Typ dokumentu
Identyfikator YADDA
JavaScript jest wyłączony w Twojej przeglądarce internetowej. Włącz go, a następnie odśwież stronę, aby móc w pełni z niej korzystać.